MedPath

Intravitreal Triamcinolone for Acute Branch Retinal Vein Occlusion

Phase 2
Completed
Conditions
Branch Retinal Vein Occlusion
Registration Number
NCT00370266
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Brief Summary

The purpose of this study is to determine whether intraocular injection of triamcinolone is effective in the treatment of macular edema in acute branch retinal vein occlusion.

Detailed Description

Intravitreal triamcinolone has recently been shown to have beneficial effect on chronic macular edema due to vein occlusion and preventive effect on neovascularization. Hypothetically, prevention of macular derangement by reducing the amount of edema from early phase after occlusion until restoration of collaterals seems to be helpful in these eyes. To our knowledge, no prospective randomized clinical trial, considering both macular changes and preventive effect on neovascularization has been published for intravitreal triamcinolone in acute branch retinal vein occlusion.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Eyes suffering from branch retinal vein occlusion with less than 2 months duration.
Exclusion Criteria
  • Monocularity,
  • Previous intraocular surgery or laser therapy
  • Glaucoma or ocular hypertension
  • Significant media opacity
  • Existence of traction on the macula
  • Visual acuity ≥20/40
  • Signs of chronicity (such as cilioretinal and/or retinal shunt vessels)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Central macular thickness
Secondary Outcome Measures
NameTimeMethod
Visual acuity
Retinal neovascularization
Intraocular pressure
Cataract progression

Trial Locations

Locations (1)

Alireza Ramezani, MD

🇮🇷

Tehran, Iran, Islamic Republic of

© Copyright 2025. All Rights Reserved by MedPath